50 results about "Interleukin 11" patented technology

The invention provides compositions containing polypeptides, including therapeutic polypeptides such as interleukin-11, that are suitable for oral administration.

The present invention demonstrates the myocardial protective effects of interleukin 11 in vivo, and provides preventive, therapeutic, or other types of drugs for heart disease using interleukin 11 as the active ingredient. The present invention, by utilizing the myocardial protective effects of interleukin 11, can suppress the progress of myocardial injury, prevent the onset of heart failure, or suppress the progress of heart failure.

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a plurality of assays, one or more of which is configured to detect a kidney injury marker selected from the group consisting of Hyaluronic acid, Immunoglobulin A, Immunoglobulin G1, Immunoglobulin G2, Insulin-like growth factor-binding protein 7, Alpha-1 antitrypsin, Serum amyloid P component, Metalloproteinase inhibitor 2, Hepatocyte growth factor, Intercellular adhesion molecule 1, Beta-2-glycoprotein 1, Interleukin-1 beta, Neutrophil Elastase, Tumor necrosis factor receptor superfamily member 11B, Interleukin-11, Cathepsin D, C—C motif chemokine 24, C—X—C motif chemokine 6, C—C motif chemokine 13, C—X—C motif chemokines -1, -2, and -3, Matrilysin, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, and Macrophage colony-stimulating factor 1 as diagnostic and prognostic biomarkers in renal injuries.

The present invention provides methods for the treatment and/or prevention of thrombocytopenia including thrombocytopenia associated with drug-induced liver damage and thrombocytopenia associated with drug-induced bone marrow destruction. The methods of treatment of the invention include administration of interleukin-11 to a subject suffering from or susceptible to thrombocytopenia and/or receiving or about to receive a treatment involving a conjugate therapeutic agent whose administration results in thrombocytopenia. Also provided are pharmaceutical compositions and kits useful for carrying out such methods of treatment.

Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

The invention discloses a preparation method and application of D-dencichine. The preparation method comprises the following steps: carrying out Fmoc protection on the amino group of D-asparagine so as to obtain a first intermediate; subjecting the first intermediate to Hoffman degradation reaction so as to obtain a second intermediate; subjecting the second intermediate to removal of Fmoc protection under the action of organic base so as to obtain a third intermediate; and subjecting the third intermediate and monomethyl oxalate to condensation reaction under a highly basic condition so as to obtain D-dencichine. D-dencichine is prepared by using the high-efficiency safe preparation method; the preparation method is simple and has high yield; the compound D-dencichine prepared by using the method has good treatment effect on thrombocytopenia and the effect is better than the effect of a clinical medicine interleukin-11, so D-dencichine can be used as a candidate medicine for treating thrombocytopenia.

The invention discloses a production method for Pichia pastoris expression recombinant human interleukin 11, which comprises the step of combined purification sequentially through reverse phase column chromatography, hydrophobic column chromatography and gel column chromatography. By adopting the production method, high-purity medicinal recombinant human interleukin 11 proteins can be prepared ina large scale.

The present invention provides for biopolymer conjugates of an IL-11 analog (mIL-11) and a biocompatible polymer. The mIL-11 of the invention displays an enhanced resistance to acidolysis and shows increased stability as compared to rhIL-11. The conjugates of the present invention are characterized by a longer serum half-life and exhibit essentially no loss of activity as compared to the corresponding unconjugated mIL-11.

The invention provides a method for preparing autologous hematopoietic stem cells. The method includes following steps of cultivating somatic cells in a cell culture fluid for 3-6 days and collecting the generated autologous hematopoietic stem cells. The cell culture fluid is an RPMI1640 culture fluid containing: 1-100 [mu]M of Y-27632 (C14H21N3O.2HCl), 1-100 ng/ml of stem cell factors, 1-100 ng/ml of interleukin 3, 1-100 ng/ml of interleukin 6, 1-100 ng/ml of interleukin 11, 1-100 ng/ml of a macrophage colony stimulating factor (M-CSF), 1-100 ng/ml of a granulocyte colony-stimulating factor (G-CSF), 1-100 [mu]g/ml of fucoidin, 1-100 [mu]g/ml of dextran sulfate, 1-100 nM of AMD3100 (1,1'-[1,4-phenylenebis(methylene)]-bis-1,4,8,11-tetrazacyclotetradecane), 1-100 [mu]M of M-alendronate sodium (Malendronate sodium trihydrate), and 1-100 [mu]M of disodium pamidronate. The invention provides a method for preparing the autologous hematopoietic stem cells, a kit, the stem cells and an application. In addition, the method is advantaged in yield, purity, and producing speed of the production of the protein-induced autologous hematopoietic stem cells.

The invention relates to an elaborate purification method of recombinant human interleukin 11 (rhIL-11). Fusion protein is desalinated by utilizing a dextran gel G-25 desalination column, the desalinated liquid is collected to carry out the cascade sample loading of negative and positive ion exchange chromatographic columns, after the sample loading is finished, the desalinated liquid is eluted by the specific Gly-NaOH buffer solution, and the collected main eluted protein solution is desalinated by the dextran gel G-25 desalination column, so that a high-purity protein sample is obtained. The method is suitable for large-scale production and is characterized in convenient operation, short production cycle, high purity of products, stable technique, etc.

The invention provides a method for preparing recombinant human interleukin-11 (rhIL). The method comprises the following steps: 1) providing a fusion protein, wherein from the N-end to the C-end, the fusion protein is thioredoxin-(His)6-proteolytic enzyme recognition site-rhIL-11 or (His)6-thioredoxin-proteolytic enzyme recognition site-rhIL-11; 2) using the proteolytic enzyme to perform enzyme cutting to the fusion protein and obtain an enzyme cutting product, wherein the enzyme cutting product contains thioredoxin and rhIL-11; and 3) using the nickel ion chelate affinity column chromatography to purify the enzyme cutting product, and performing gradient elution to the column to obtain rhIL-11, wherein the thioredoxin and the rhIL-11 are both adsorbed on the column. By adopting the method provided by the invention, the rhIL-11 can be purified rapidly, conveniently and efficiently and the recovery rate can be greatly increased.

The present invention relates to mainly one system of efficient culturing and directive inducing stem cell differentiation for culturing and proliferating megakaryocyte. The system has umbilical cord blood and marrow stem cell as seed cell, and the serum-free culture medium comprising TPO, IL-11 and heparin as the main component for megakaryocyte proliferation. The megakaryocyte preparation prepared based on the present invention contains great amount of macronucleus ancestral cells and mature megakaryocyte as well as CD34+ cells, and has the functions of treating thrombocytopenia and improving the blood-forming function after stem cell transplantation. The present invention provides novel efficient cell treating preparation for various thrombocytopenia and hemocyitopenia.

Provided by the present invention are topical formulations of Interleukin-11 and methods for treating a variety of disorders, including inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis, indeterminate colitis, and infectious colitis), mucositis (e.g., oral mucositis, gastrointestinal mucositis, nasal mucositis, and proctitis), necrotizing enterocolitis, inflammatory skin disorders (e.g., psoriasis, atopic dermatitis, and contact hypersensitivity), aphthous ulcers, pharyngitis, esophagitis, peptic ulcers, gingivitis, periodontitis, and ocular diseases (e.g., conjunctivitis, retinitis, and uveitis).

The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of Cancer antigen CA 15-3, C-C Motif chemokine 18, C-C Motif chemokine 24, Cathepsin D, C-X-C Motif chemokine 13, C-C motif chemokine 8, Interleukin-2 receptor alpha chain, Insulin-like growth factor-binding protein 3, Interleukin-11, Matrix Metalloproteinase-8, Transforming growth factor alpha, IgG1, and IgG2 as diagnostic and prognostic biomarkers in renal injuries.

A compound medicine for arresting bleeding is characterized in that the compound medicine is a mixture of a batroxobin and an interleukin-11; the clinical dosage of the batroxobin is 0.01-10u and that of IL-11 is 0.06-50mg; the batroxobin is the batroxobin from snake venom of Brazilian spearhead adder, white-eyebrow adder or acutus adder, or the batroxobin from recombinant Brazilian spearhead adder, white-eyebrow adder or acutus adder obtained by genetic engineering; the interleukin-11 is produced by human bone-marrow stromal cells (fibroblasts) and interstitial cells, or the recombinant IL-11 by genetic engineering. The medicine for arresting bleeding can not only ensure the curative effect but also decrease the amount of protease so as to reduce the rate of adverse immune response.

The invention discloses a method for preparing medicinal recombinant human interleukin-11, which adopts the following preparation steps of: 1) initial purification of a fusion protein in the interleukin-11, which comprises steps of crushing thalli and separating a chelate column; 2) digesting the fusion protein containing the interleukin-11 by enterokinase; and 3) fine purification of the interleukin-11, wherein Macro Cap SP column chromatography and Superdex-75 column chromatography are carried out to obtain the medicinal recombinant human interleukin-11. The method has the characteristics of simple process, high expression amount, high stability, uniform product, low production cost, environmental protection and high activity, improves the safety, controllability and validity of medicaments and is suitable for industrial production.

The present invention provides methods for the treatment and/or prevention of thrombocytopenia including thrombocytopenia associated with drug-induced liver damage and thrombocytopenia associated with drug-induced bone marrow destruction. The methods of treatment of the invention include administration of interleukin-11 to a subject suffering from or susceptible to thrombocytopenia and/or receiving or about to receive a treatment involving a conjugate therapeutic agent whose administration results in thrombocytopenia. Also provided are pharmaceutical compositions and kits useful for carrying out such methods of treatment.

Methods of treating and preventing hepatotoxicity through inhibiting interleukin 11 (IL-11)-mediated signalling are disclosed, as well as agents for use in such methods.